Tianda Pharmaceuticals First Half 2025 Earnings: HK$0.015 loss per share (vs HK$0.013 loss in 1H 2024)
Tianda Pharmaceuticals (HKG:455) First Half 2025 Results
Key Financial Results
- Revenue: HK$136.6m (down 13% from 1H 2024).
- Net loss: HK$33.2m (loss widened by 22% from 1H 2024).
- HK$0.015 loss per share (further deteriorated from HK$0.013 loss in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tianda Pharmaceuticals shares are down 14% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Tianda Pharmaceuticals (including 1 which is significant).
Valuation is complex, but we're here to simplify it.
Discover if Tianda Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:455
Tianda Pharmaceuticals
Engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.
Good value with imperfect balance sheet.
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives
Microsoft will achieve a future PE ratio of 24.626979x by leveraging strong growth
Strong DAU drives Ads and AI Data narrative

Silver X Has 152 Million Ounces, Already Producing and Its Biggest Growth Phase May Still Be Ahead
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years
